Credit: Shutterstock. Tepezza is a human insulin-like growth factor-1 receptor inhibitor. The Indications and Usage section of the Tepezza ® (teprotumumab-trbw) prescribing information has been ...

A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to file for FDA approval next year and challenge Amgen for a blockbuster ...

Tepezza is an intravenous medication that may help treat thyroid eye disease (TED) by addressing immune system activity behind the eyes. Possible side effects of Tepezza include hearing issues, ...

Concerning reports indicate the newly-approved Thyroid Eye Disease (TED) medication Tepezza could cause hearing loss and tinnitus. TED is the most common orbital disorder in adults, with a ...

Credit: Getty Images. Tepezza is a human insulin-like growth factor-1 receptor inhibitor. Tepezza ® (teprotumumab-trbw) significantly reduced proptosis in adults with chronic thyroid eye disease (TED) ...

Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) trial, teeing the biotech up to run a confirmatory study of its ...

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- TEPEZZA Market Sales on the Rise Due to the Strong Growth Driven by Demand for Thyroid Eye Disease Treatment | DelveInsight TEPEZZA, as the first ...

Christy Bieber has a JD from UCLA School of Law and began her career as a college instructor and textbook author. She has been writing full time for over a decade with a focus on making financial and ...

Please provide your email address to receive an email when new articles are posted on . Tepezza demonstrated promising re-treatment rates in patients with thyroid eye disease. Age may be a significant ...

Hearing problems were a common side effect reported in studies of Tepezza (teprotumumab-trbw). These include hearing loss, which may lead to deafness. Share on Pinterest aquaArts studio/Getty Images ...